Gordon Carl L
CIK 0001282930 Name as filed on the most recent filing
Filed as Gordon Carl L (58)
160 transaction lines · from 58 filings · filed 2004-06-04 to 2026-08-12 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
- ISSUER BlossomHill Therapeutics, Inc. 1 filings
- ISSUER Scribe Therapeutics, Inc. 1 filings
- ISSUER Compass Therapeutics, Inc. 6 filings
- ISSUER MBX Biosciences, Inc. 2 filings
- ISSUER Keros Therapeutics, Inc. 2 filings
- ISSUER Terns Pharmaceuticals, Inc. 4 filings
- ISSUER BiomX Inc. 2 filings
- ISSUER ArriVent Biopharma, Inc. 1 filings
- ISSUER Adicet Bio, Inc. 2 filings
- ISSUER Theseus Pharmaceuticals, Inc. 5 filings
- ISSUER Kinnate Biopharma Inc. 4 filings
- ISSUER Oric Pharmaceuticals, Inc. 6 filings
- ISSUER Prevail Therapeutics Inc. 1 filings
- ISSUER Turning Point Therapeutics, Inc. 1 filings
- ISSUER Alector, Inc. 1 filings
- ISSUER Arsanis, Inc. 1 filings
- ISSUER Selecta Biosciences Inc 1 filings
- ISSUER Intellia Therapeutics, Inc. 1 filings
- ISSUER Amarin Corp Plc\Uk 12 filings
- ISSUER Pacira Pharmaceuticals, Inc. 1 filings
- ISSUER Biocryst Pharmaceuticals Inc 1 filings
- ISSUER Acadia Pharmaceuticals Inc 2 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
158 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-10 |
BlossomHill Therapeutics, Inc. BLSM |
P, Open-market purchase | 625,000 acquired | 16.00 | 10,000,000.00 | Form 4, filing 0000947871-26-000785 | |
| 2026-07-27 |
Scribe Therapeutics, Inc. SCTX |
P, Open-market purchase | 1,000,000 acquired | 15.00 | 15,000,000.00 | Form 4, filing 0000947871-26-000734 | |
| 2025-04-09 |
Compass Therapeutics, Inc. CMPX |
S, Open-market sale | 3,571,428 disposed | 1.59 | 5,678,570.52 | Form 4, filing 0000947871-25-000385 | |
| 2025-02-18 |
MBX Biosciences, Inc. MBX |
P, Open-market purchase | 94,100 acquired | 10.84 | 1,020,044.00 | Form 4, filing 0000947871-25-000200 | |
| 2025-02-18 |
MBX Biosciences, Inc. MBX |
P, Open-market purchase | 49,070 acquired | 10.84 | 531,918.80 | Form 4, filing 0000947871-25-000200 | |
| 2025-02-14 |
MBX Biosciences, Inc. MBX |
P, Open-market purchase | 29,540 acquired | 9.85 | 290,969.00 | Form 4, filing 0000947871-25-000200 | |
| 2025-02-14 |
MBX Biosciences, Inc. MBX |
P, Open-market purchase | 17,962 acquired | 9.90 | 177,823.80 | Form 4, filing 0000947871-25-000200 | |
| 2024-09-16 |
MBX Biosciences, Inc. MBX |
P, Open-market purchase | 500,000 acquired | 16.00 | 8,000,000.00 | Form 4, filing 0000950170-24-107524 | |
| 2024-09-16 |
MBX Biosciences, Inc. MBX |
P, Open-market purchase | 250,000 acquired | 16.00 | 4,000,000.00 | Form 4, filing 0000950170-24-107524 | |
| 2024-08-13 |
Keros Therapeutics, Inc. KROS |
S, Open-market sale | 220,600 disposed | 44.01 | 9,708,606.00 | Form 4, filing 0000947871-24-000703 | |
| 2024-08-13 |
Keros Therapeutics, Inc. KROS |
S, Open-market sale | 29,400 disposed | 44.01 | 1,293,894.00 | Form 4, filing 0000947871-24-000703 | |
| 2024-07-16 |
Terns Pharmaceuticals, Inc. TERN |
S, Open-market sale | 4,009 disposed | 10.00 | 40,090.00 | Form 4, filing 0000947871-24-000628 | |
| 2024-07-16 |
Terns Pharmaceuticals, Inc. TERN |
S, Open-market sale | 623 disposed | 10.00 | 6,230.00 | Form 4, filing 0000947871-24-000628 | |
| 2024-07-16 |
Terns Pharmaceuticals, Inc. TERN |
S, Open-market sale | 556 disposed | 10.00 | 5,560.00 | Form 4, filing 0000947871-24-000628 | |
| 2024-07-15 |
Terns Pharmaceuticals, Inc. TERN |
S, Open-market sale | 39,433 disposed | 10.00 | 394,330.00 | Form 4, filing 0000947871-24-000628 | |
| 2024-07-15 |
Terns Pharmaceuticals, Inc. TERN |
S, Open-market sale | 6,142 disposed | 10.00 | 61,420.00 | Form 4, filing 0000947871-24-000628 | |
| 2024-07-15 |
Terns Pharmaceuticals, Inc. TERN |
S, Open-market sale | 5,401 disposed | 10.00 | 54,010.00 | Form 4, filing 0000947871-24-000628 | |
| 2024-05-15 |
BiomX Inc. PHGE |
S, Open-market sale | 24,344 disposed | 0.38 | 9,279.93 | Form 4, filing 0000947871-24-000498 | |
| 2024-01-30 |
ArriVent Biopharma, Inc. AVBP |
P, Open-market purchase | 222,222 acquired | 18.00 | 3,999,996.00 | Form 4, filing 0001104659-24-008797 | |
| 2024-01-30 |
ArriVent Biopharma, Inc. AVBP |
P, Open-market purchase | 222,222 acquired | 18.00 | 3,999,996.00 | Form 4, filing 0001104659-24-008797 | |
| 2024-01-25 |
Adicet Bio, Inc. ACET |
P, Open-market purchase | 1,841,100 acquired | 2.40 | 4,418,640.00 | Form 4, filing 0000950170-24-008052 | |
| 2024-01-25 |
Adicet Bio, Inc. ACET |
P, Open-market purchase | 1,041,700 acquired | 2.40 | 2,500,080.00 | Form 4, filing 0000950170-24-008052 | |
| 2024-01-25 |
Adicet Bio, Inc. ACET |
P, Open-market purchase | 242,200 acquired | 2.40 | 581,280.00 | Form 4, filing 0000950170-24-008052 | |
| 2023-07-17 |
Theseus Pharmaceuticals, Inc. THRX |
P, Open-market purchase | 328,482 acquired | 3.05 | 1,001,870.10 | Form 4, filing 0000947871-23-000761 | |
| 2023-07-17 |
Theseus Pharmaceuticals, Inc. THRX |
P, Open-market purchase | 151,450 acquired | 3.05 | 461,922.50 | Form 4, filing 0000947871-23-000761 | |
| 2023-06-27 |
Adicet Bio, Inc. ACET |
P, Open-market purchase | 442,000 acquired | 2.09 | 923,780.00 | Form 4, filing 0000947871-23-000714 | |
| 2023-06-27 |
Adicet Bio, Inc. ACET |
P, Open-market purchase | 250,000 acquired | 2.09 | 522,500.00 | Form 4, filing 0000947871-23-000714 | |
| 2023-06-27 |
Adicet Bio, Inc. ACET |
P, Open-market purchase | 125,000 acquired | 2.09 | 261,250.00 | Form 4, filing 0000947871-23-000714 | |
| 2023-06-27 |
Adicet Bio, Inc. ACET |
P, Open-market purchase | 58,000 acquired | 2.09 | 121,220.00 | Form 4, filing 0000947871-23-000714 | |
| 2023-05-05 |
Kinnate Biopharma Inc. KNTE |
P, Open-market purchase | 490,512 acquired | 2.82 | 1,383,243.84 | Form 4, filing 0000947871-23-000540 | |
| 2023-05-05 |
Kinnate Biopharma Inc. KNTE |
P, Open-market purchase | 490,511 acquired | 2.82 | 1,383,241.02 | Form 4, filing 0000947871-23-000540 | |
| 2023-05-04 |
Kinnate Biopharma Inc. KNTE |
P, Open-market purchase | 312,991 acquired | 2.75 | 860,725.25 | Form 4, filing 0000947871-23-000540 | |
| 2023-05-04 |
Kinnate Biopharma Inc. KNTE |
P, Open-market purchase | 83,459 acquired | 2.75 | 229,512.25 | Form 4, filing 0000947871-23-000540 | |
| 2023-05-04 |
Kinnate Biopharma Inc. KNTE |
P, Open-market purchase | 83,459 acquired | 2.75 | 229,512.25 | Form 4, filing 0000947871-23-000540 | |
| 2023-05-02 |
Kinnate Biopharma Inc. KNTE |
P, Open-market purchase | 220,610 acquired | 2.67 | 589,028.70 | Form 4, filing 0000947871-23-000516 | |
| 2023-05-02 |
Kinnate Biopharma Inc. KNTE |
P, Open-market purchase | 58,826 acquired | 2.67 | 157,065.42 | Form 4, filing 0000947871-23-000516 | |
| 2023-05-02 |
Kinnate Biopharma Inc. KNTE |
P, Open-market purchase | 58,826 acquired | 2.67 | 157,065.42 | Form 4, filing 0000947871-23-000516 | |
| 2023-05-01 |
Kinnate Biopharma Inc. KNTE |
P, Open-market purchase | 467,068 acquired | 2.62 | 1,223,718.16 | Form 4, filing 0000947871-23-000516 | |
| 2023-05-01 |
Kinnate Biopharma Inc. KNTE |
P, Open-market purchase | 124,545 acquired | 2.62 | 326,307.90 | Form 4, filing 0000947871-23-000516 | |
| 2023-05-01 |
Kinnate Biopharma Inc. KNTE |
P, Open-market purchase | 124,544 acquired | 2.62 | 326,305.28 | Form 4, filing 0000947871-23-000516 | |
| 2023-04-28 |
Kinnate Biopharma Inc. KNTE |
P, Open-market purchase | 228,754 acquired | 2.55 | 583,322.70 | Form 4, filing 0000947871-23-000516 | |
| 2023-04-28 |
Kinnate Biopharma Inc. KNTE |
P, Open-market purchase | 60,998 acquired | 2.55 | 155,544.90 | Form 4, filing 0000947871-23-000516 | |
| 2023-04-28 |
Kinnate Biopharma Inc. KNTE |
P, Open-market purchase | 60,997 acquired | 2.55 | 155,542.35 | Form 4, filing 0000947871-23-000516 | |
| 2023-02-27 |
BiomX Inc. PHGE |
P, Open-market purchase | 348,000 acquired | 0.24 | 85,260.00 | Form 4, filing 0000947871-23-000336 | |
| 2022-12-23 |
Terns Pharmaceuticals, Inc. TERN |
P, Open-market purchase | 137,931 acquired | 7.25 | 999,999.75 | Form 4, filing 0000947871-22-001259 | |
| 2022-11-08 |
Compass Therapeutics, Inc. CMPX |
P, Open-market purchase | 402,000 acquired | 3.21 | 1,290,420.00 | Form 4, filing 0000947871-22-001163 | |
| 2022-11-07 |
Theseus Pharmaceuticals, Inc. THRX |
P, Open-market purchase | 192,000 acquired | 5.21 | 1,000,320.00 | Form 4, filing 0000947871-22-001158 | |
| 2022-08-16 |
Terns Pharmaceuticals, Inc. TERN |
P, Open-market purchase | 2,470,200 acquired | 2.42 | 5,977,884.00 | Form 4, filing 0000947871-22-000910 | |
| 2022-08-16 |
Terns Pharmaceuticals, Inc. TERN |
P, Open-market purchase | 762,400 acquired | 2.42 | 1,845,008.00 | Form 4, filing 0000947871-22-000910 | |
| 2022-08-16 |
Terns Pharmaceuticals, Inc. TERN |
P, Open-market purchase | 457,400 acquired | 2.42 | 1,106,908.00 | Form 4, filing 0000947871-22-000910 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- P, Open-market purchase
- Open-market purchase
- S, Open-market sale
- Open-market sale
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.
- Open-market purchase 84
- Open-market sale 74
- Option exercise 0
- Grant or award 0
- Tax withholding 0
- Disposition to the issuer 0
- In-the-money option exercise 0
How to cite this page
ebomi catalog. GORDON CARL L, insider transactions. Retrieved 2026-08-20 from https://ebomi.com/insider/0001282930
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6